KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMD) Shares Outstanding (2016 - 2025)

LifeMD (LFMD) has disclosed Shares Outstanding for 14 consecutive years, with $46.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 3240.0% year-over-year to $46.8 million, compared with a TTM value of $46.8 million through Dec 2025, up 3240.0%, and an annual FY2025 reading of $46.8 million, up 3240.0% over the prior year.
  • Shares Outstanding was $1.4 million for Q4 2025 at LifeMD, down from $46.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $46.7 million in Q3 2025 and bottomed at $1.4 million in Q4 2021.
  • Average Shares Outstanding over 5 years is $15.9 million, with a median of $1.4 million recorded in 2021.
  • Peak annual rise in Shares Outstanding hit 3240.0% in 2025, while the deepest fall reached 96.56% in 2025.
  • Year by year, Shares Outstanding stood at $1.4 million in 2021, then changed by 0.0% to $1.4 million in 2022, then skyrocketed by 2639.9% to $38.4 million in 2023, then crashed by 96.35% to $1.4 million in 2024, then surged by 3240.0% to $46.8 million in 2025.
  • Business Quant data shows Shares Outstanding for LFMD at $46.8 million in Q4 2025, $1.4 million in Q3 2025, and $1.4 million in Q2 2025.